Literature DB >> 11036160

Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.

R J Briscoe1, C L Cabrera, T J Baird, K C Rice, J H Woods.   

Abstract

Central administration of CRH results in endocrinological, cardiovascular, and behavioral effects that suggest stress or anxiety. Among these is a marked pressor response. Parenteral administration of CRH, however, results in hypotension. We used parenteral administration of antalarmin, a novel, small molecule CRH1 receptor antagonist, and alpha-helical CRH(9-41), a peptidic CRHR1/CRHR2 antagonist to attempt to determine the receptor mechanisms through which CRH is acting in both of these situations. Our results suggest that the hypertension produced by central CRH administration is mediated through central CRHR1 receptors, whereas the hypotension produced by parenteral CRH administration is mediated through peripheral CRHR2 receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036160     DOI: 10.1016/s0006-8993(00)02742-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist.

Authors:  Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-24       Impact factor: 3.619

2.  The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors.

Authors:  Udi E Ghitza; Sarah M Gray; David H Epstein; Kenner C Rice; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2005-12-07       Impact factor: 7.853

3.  Corticotropin-releasing factor modulation of forebrain GABAergic transmission has a pivotal role in the expression of anabolic steroid-induced anxiety in the female mouse.

Authors:  Joseph G Oberlander; Leslie P Henderson
Journal:  Neuropsychopharmacology       Date:  2012-02-01       Impact factor: 7.853

4.  Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats.

Authors:  Susan K Wood; Robert E Verhoeven; Aaron Z Savit; Kenner C Rice; Peter S Fischbach; James H Woods
Journal:  Neuropsychopharmacology       Date:  2006-05-03       Impact factor: 7.853

5.  CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats.

Authors:  M Million; L Wang; Y Wang; D W Adelson; P-Q Yuan; C Maillot; S V Coutinho; J A Mcroberts; A Bayati; H Mattsson; V Wu; J-Y Wei; J Rivier; W Vale; E A Mayer; Y Taché
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

6.  CRHR2 (Corticotropin-Releasing Hormone Receptor 2) in the Nucleus of the Solitary Tract Contributes to Intermittent Hypoxia-Induced Hypertension.

Authors:  Lei A Wang; Dianna H Nguyen; Steve W Mifflin
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

7.  Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Zhihui Yang; Marcelo Febo; Zhiying Shan; Kevin K W Wang; Adriaan W Bruijnzeel
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-22       Impact factor: 4.600

8.  The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.

Authors:  Peter W Marinelli; Douglas Funk; Walter Juzytsch; Stephen Harding; Kenner C Rice; Yavin Shaham; A D Lê
Journal:  Psychopharmacology (Berl)       Date:  2007-08-20       Impact factor: 4.530

9.  On the role of corticotropin-releasing hormone receptors in anxiety and depression.

Authors:  Johannes M H M Reul; Florian Holsboer
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

10.  Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.

Authors:  Bhimanna Kuppast; Katerina Spyridaki; Christophina Lynch; Yueshan Hu; George Liapakis; Gareth E Davies; Hesham Fahmy
Journal:  Med Chem       Date:  2014       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.